RxSight IPO

RxSight is the developer of the first and only adjustable intraocular lens (IOL) that is customized after cataract surgery, enabling doctors and patients to predictably optimize vision after cataract surgery through an office based IOL enhancement.

Register for Details

For more details on financing and valuation for RxSight, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is RxSight's ticker symbol?

RXST

What is RxSight's stock price?

26.03 as of 6/2/23

Learn more about RxSight

Forge green plus iconForge green minus icon

What is RxSight funding to date?

RxSight has raised $179.84MM.
Updated on: Jun 12, 2022